Treatment of boys with X-linked adrenoleukodystrophy (ALD) with Lorenzo’s oil (LO) reduced their risk of developing the severe debilitating form of the disease, according to a study in the July issue of the Archives of Neurology, one of the JAMA/Archives journals.
Eleven patients with Parkinson’s disease (PD) developed pathological gambling behavior following dopamine agonist therapy, a drug therapy to control movement problems caused by Parkinson’s disease, according to a study posted online today which will appear in the September print issue of the Archives of Neurology, one of the JAMA/Archives journals.
A multicenter study of a pill that combines two drugs for hypertension shows significant benefit for people with hard-to-control high blood pressure. The study, conducted at the University of Maryland School of Medicine and 118 other sites, was focused on bringing down systolic blood pressure, the top number in a blood pressure reading, which is the more difficult number to bring down.
New data from two leading clinical studies show Lucentis is first therapy to improve vision in patients with wet age-related macular degeneration (AMD). AMD is leading cause of blindness for people over age 50.
Xolair? (omalizumab) add-on therapy significantly reduces attacks in patients with severe allergic asthma. Separate analysis shows first humanised antibody for allergic asthma reduces dependence on steroids to manage attacks.
Scientists supported by the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health, have added a key new piece to the puzzle of how tumor cells induce new blood vessels to form and fuel their abnormal growth, a well-known process called angiogenesis.
A stopwatch-sized device that uses electrical impulses to treat chronic depression won U.S. Food and Drug Administration approval.
Interleukin-2 (IL-2), an immune-boosting drug used experimentally in HIV therapy, greatly increases the lifespan of certain subsets of immune system T cells in some HIV-positive people who respond to this therapy, discovered researchers from the National Institutes of Health (NIH) Clinical Center and the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. A report describing the study, led by the Clinical Center?s Joseph A. Kovacs, M.D., appears online today in The Journal of Clinical Investigation.
Some women who use a combination of estrogen and progestin to control the symptoms of menopause might find symptoms return when they stop the hormones, according to the latest findings from the Women?s Health Initiative (WHI), a major clinical trial of the risks and benefits of menopausal hormone therapy supported by the National Institutes of Health (NIH).
An NIMH-sponsored randomized controlled trial offers physicians new guidance on what treatments are effective for complicated grief, a disorder associated with negative (and sometimes debilitating) health consequences.